Roth Capital Begins Coverage on Aptevo Therapeutics (APVO)

Roth Capital initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued to investors on Wednesday, April 11th, Marketbeat.com reports. The firm issued a buy rating and a $12.00 price objective on the biotechnology company’s stock.

Shares of APVO stock opened at $4.31 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.14 and a quick ratio of 5.08. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.85.

How to Become a New Pot Stock Millionaire

In related news, insider Marvin L. White sold 100,000 shares of the company’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $2.93, for a total value of $293,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 15.60% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in shares of Aptevo Therapeutics during the 4th quarter valued at about $690,000. Victory Capital Management Inc. bought a new position in shares of Aptevo Therapeutics during the 4th quarter valued at about $827,000. Acadian Asset Management LLC raised its position in shares of Aptevo Therapeutics by 87.2% during the 4th quarter. Acadian Asset Management LLC now owns 67,799 shares of the biotechnology company’s stock valued at $287,000 after buying an additional 31,578 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Aptevo Therapeutics by 411.8% during the 4th quarter. Renaissance Technologies LLC now owns 428,400 shares of the biotechnology company’s stock valued at $1,816,000 after buying an additional 344,700 shares in the last quarter. 33.04% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Roth Capital Begins Coverage on Aptevo Therapeutics (APVO)” was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://weekherald.com/2018/04/18/roth-capital-begins-coverage-on-aptevo-therapeutics-apvo.html.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply